International Stem Cell Corp. (OTCMKTS:ISCO) Sees Significant Increase in Short Interest

International Stem Cell Corp. (OTCMKTS:ISCO) was the recipient of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 9,559 shares, a growth of 24,410.3% from the January 15th total of 39 shares. Currently, 0.7% of the shares of the company are short sold. Based on an average daily trading volume, of 16,687 shares, the short-interest ratio is presently 0.6 days. Based on an average daily trading volume, of 16,687 shares, the short-interest ratio is presently 0.6 days. Currently, 0.7% of the shares of the company are short sold.

International Stem Cell Stock Performance

Shares of International Stem Cell stock opened at $0.17 on Wednesday. The firm has a 50-day moving average of $0.14 and a 200-day moving average of $0.14. International Stem Cell has a 52-week low of $0.08 and a 52-week high of $0.27. The stock has a market cap of $1.32 million, a PE ratio of -8.25 and a beta of 0.24.

About International Stem Cell

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.